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Abstract
Background: The novel compound 1a is one of the isoflavone fatty acid esters. In order to investigate the anti-obesity 
effect of compound 1a and its potential mechanism of influence in adipocyte differentiation, Obese male C57BL/6J 
mice induced by high-fat diet (HFD) and rat preadipocytes (3T3-L1 cell) were used.
Methods: After 4-week HFD induction, the obese model was made successfully. After treatment with compound 1a, 
mice plasma biochemistry parameters were analyzed. In addition, mice hepatic tissue slice was observed. In in vitro 
research, 3T3-L1 cell differentiation by Oil-Red-O staining and adipocyte apoptosis was detected by flow cytometry.
Results: The in vivo results implied that compound 1a significantly decreased the body weight, white adipose tissue 
weight of obesity mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated HDL-C in serum(p < 0.05). The in 
vitro results suggested that compound 1a could significantly suppress the adipocyte viability and lipid accumulation in 
the differentiation of preadipocyte, and induce apoptosis in both preadipocytes and mature adipocytes(p < 0.05).
Conclusion: Compound 1a regulates serum lipid profiles, decreases adipose tissue mass and body weight gain by 
inducing adipocyte apoptosis in high fat diet induced mice. Thus, it may be used to treat obese patients with 
hypercholesterolemia and hypertriglyceridemia.
Background
Obesity, which results from a prolonged energy imbal-
ance during which intake exceeds expenditure, is a rap-
idly growing epidemic in modernized world [1] and is a
major risk factor for several serious chronic diseases,
such as type 2 diabetes, cardiovascular disease, hyperten-
sion, stroke, asthma, and certain forms of cancer [2].
Considerable effort has been devoted to the discovery of
anti-obesity drugs worldwide. Though there are dozens
of potential targets for anti-obesity, only three agents,
sibutramine (Reductil® or Meridia®), an appetite suppres-
sant orlistat (Xenical®), an inhibitor of fat absorption and
rimonaban, a CB1 antagonist, have been introduced into
the market during recent years [3]. But several serious
adverse effects of sibutramine, orlistat and rimonaban
were reported in clinical practice, including gastrointesti-
nal adverse effect and significant unfavorable effects on
cardiovascular system [4-6]. The difficulty to lose exces-
sive weight is tightly linked to the complexity and redun-
dancy within lipid systems, which involve an intricate
network of peripheral signals and neuronal circuits, con-
stitute obstacles to seek effective potential targets for
anti-obesity treatments [7]. In the peripheral organiza-
tions, the fat tissue plays an important role in maintaining
the energy balance. It is not only an energy storage organ,
but also a secretion one. It produces and secretes dozens
of factors such as leptin, adiponectin, resistin, visfatin,
tumor necrosis factor-α(TNF-α), and interleukin-6 (IL-
6), which participate in the energy metabolism of adipose
tissue itself and the whole body either in an auto/para-
crine or an endocrine fashion [8-11]. Obesity is charac-
terized by an increase in the number and size of
adipocytes differentiated from fibloblastic preadipocytes
in adipose tissues [12].
Adipocytes play a vital role in regulating adipose mass
and obesity, in relation not only to lipid homeostasis and
energy balance but also to secreting transcription factors
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[13]. 3T3-L1 cells have been served as well-established in
vitro model to assess adipogenesis and adipocyte differ-
entiation [14]. The programmed differentiation of preadi-
pocytes into adipocytes involves several stages related to
obesity [15]. For these reasons, many research efforts
have been conducted in 3T3-L1 cells to search for new
health benefit foods/agents for obesity or weight control.
Potential therapeutic agents that inhibit adipogenesis or
increase adipocyte death by apoptosis could be important
tools in preventing obesity [16].
Isoflavones are found at high levels in soy plants and
structurally similar to estrogens [17]. They are suggested
to be a potential alternative to estrogen therapy in the
treatment and prevention of menopausal symptoms,
osteoporosis, breast cancer and cardiovascular disease.
Genistein, daidzein, glycitein, formononetin and biocha-
nin A are considered to be the most important and hence
most studied isoflavone phytoestrogens [18,19]. It is also
reported that isoflavones have healthful benefits in
human obesity and have a positive influence on plasma
cholesterol [20].
Here in this paper we defined 4'-methoxy daidzein-7-
fatty acid esters as compound 1a (Fig.1).
We performed research to evaluate the anti- dyslipi-
demia effect of compound 1a and its potential mecha-
nism in adipocyte differentiation.
Materials and methods
Material
Compound  1a  was provided by China pharmaceutical
university. Dulbecco's modified Eagle's medium
(DMEM), fetal bovine serum (FBS) were purchased from
Gibco BRL of Invitrogen Corporation (Carlsbad, CA).
Methylisobutylxanthine, hochest 33342 dye, MTT and
Oil-Red-O were obtained from Sigma (St. Louis, MO).
Dexamethasone was purchased from Xianju Pharmaceu-
tical Co.Ltd (Zhejiang, China). Insulin was purchased
from Wanbang Pharmaceutical Co.Ltd (Xuzhou, China).
Leptin ELISA kit was obtained from Boster (Wuhan,
China). Anannexin V-fluorescein isothiocyanate (FITC)
Apoptosis kit was provided by KeyGene (Nanjing,
China). All other reagents were of analytical grade.
Animals and diets
Fifty male C57BL/6J mice initially weighing 16.03 ± 1.22 g
from Nanjing University Animal Center were used. The
animals were housed in 12 h light/dark cycle (light on
7a.m.), temperature 22°C, and allowed adlibitum access
to diet and water.
Animal groups
After one week's acclimatization period, 50 mice were
divided randomly into two groups: the normal group (n =
10) were fed with low fat diet (LFD), whereas the experi-
mental group (n = 40) were fed with high-fat diet (HFD).
After 4-week induction, the obese model was made
successfully. The 40 obese mice were divided into four
groups (n = 10/each group): model group, low dosage
group (50 mg·kg-1 compound 1a), high dosage group (100
mg·kg-1 compound 1a) and control group (200 mg·kg-1
Inositol Hexanicotinate) respectively.
HFD composition
HFD was composed with 90.5% basal diet, 2% cholesterol,
0.5% propacil and 7% grease.
Adiminstration modality
Drugs were intragastric administration with suspension
in olive oil (0.1 ml/10 g) at 9 A.M. The normal group and
model group were administered only olive oil. After 4
weeks, animals were fasted overnight. Next day, blood
samples were collected fast from the retroorbital sinus
into tubes; serum was separated and stored at -80°C until
analysis. Then animals were sacrificed by cervical dislo-
cation and tissues were harvested, weighed, snap frozen
in liquid nitrogen and stored at -80°C until use. All animal
experiments were approved by the Institutional Animal
Care and Use Committees of Nanjing Medical University,
and followed National Research Council Guidelines.
Biochemical analysis
In serum, total cholesterol (TC), high density lipoprotein
cholesterol (HDL-C), low density lipoprotein cholesterol
(LDL-C) and triglyceride (TG) were measured by Auto-
matic Analyzer 7170A (Hitavhi, Jap.). Serum leptin was
detected through leptin ELISA kit (Boster, China).
Histological analysis
The right lobe of rat liver was fixed in 10% phosphate-
buffered formalin for one day and processed in a routine
manner to generate 3 μm thick paraffin sections, which
were stained with hematoxylin and eosin (HE) and sub-
jected to microscopic examination.
Cell culture
3T3-L1 preadipocytes were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS). After cell
reached 80% confluence, the preadipocytes were induced
with 1 mg·mL-1  insulin (Wanbang), 1 mmol·L-1  DEX
(Xianju) and 0.5 mmol·L-1 MIX (Sigma) (MDI) in DMEM
supplemented with 10% fetal bovine serum. After 48 h,
the culture medium was replaced with DMEM supple-
mented with 10% fetal bovine serum and 1 mg·mL-1 insu- Figure 1 Structural formula of compound 1a.Yao et al. Lipids in Health and Disease 2010, 9:49
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lin, which was switched to DMEM containing 10% fetal
bovine serum 2 days later. Cytoplasmic triglyceride drop-
lets were visible under the fluorescence microscope (Carl
Ziess Axiovert 40 CFL). For the following experiments,
preadipocytes and mature adipocytes were treated for 48
h. All compounds, stock solutions were prepared in
DMSO and filter sterilized.
Cell Viability
All the tests were done in 96-well plates. For non-matur-
ing preadipocyte experiments, cells were seeded (5 × 103
cells/well) and grown until they reached confluence, and
then treated with the compounds or vehicle (DMSO).
After the cells were treated with compound 1a for the 48
h, MTT (Sigma) solution 20 μL (0.5 mg·mL-1) was added
into the cell culture medium, and the cells were incubated
at 37°C and 5% CO2 for 4 h. The MTT formazan crystals
were then dissolved with 150 μL DMSO and the absor-
bance in individual wells was determined at 570 nm by a
microplate reader (Labsystems Multiskan Ascent). The
inhibition of cell growth was evaluated by the MTT
method by using triplicate assay. The inhibition ratio was
calculated thorough the formula 1.
Oil-Red-O staining
For Oil-Red-O staining [21], cells were washed gently
with phosphate buffered saline (PBS) twice, fixed with
3.7% fresh formaldehyde (Sigma) in PBS for 1 h at room
temperature and stained with filtered Oil-Red-O (Sigma)
solution (60% isopropanol and 40% water) for at least 1 h.
After staining of lipid droplets with red, the Oil-Red-O
staining solution was removed and the plates were rinsed
with water and dried. Images of the stained lipid droplets
were collected on a fluorescence microscope (Carl Ziess
Axiovert 40 CFL). The inhibition ratio of lipid production
was calculated through formula 1.
Measurement of the triglyceride content
Cells were seeded in 96-well plates. 3T3-L1 adipocyte
monolayer was washed three times with phosphate-buff-
ered saline (PBS) and then fixed for 30 min with 3.7%
formaldehyde in PBS. Oil-Red-O (0.5%) in isopropanol
was diluted with 2/3 volumes of water, filtered and added
to the fixed cell monolayer for 1 h at room temperature.
The cell monolayer was then washed with PBS, and the
stained triglyceride droplets in the cells were visualized.
Finally, the dye retained in the cells was eluted with iso-
propanol and quantified by measuring the optical absor-
bance at 492 nm by a microplate reader (Labsystems
Multiskan Ascent). The inhibition of lipid accumulation
was evaluated by using triplicate assay.
Apoptosis assays
Chromatin Staining with Hoechst 33342
Cells were fixed with 3.7% para-formaldehyde for 30 min,
and then stained with 10 μmol·L-1 Hoechst 33342 dye
(Sigma) for 30 min in the dark. After staining, cells were
observed by fluorescence microscopy (Carl Ziess Axio-
vert 40 CFL). Cells with bright blue fragmented nuclei
showing condensation of chromatin were identified as
apoptotic cells.
Flow cytometry
Phosphatidylserine exposed on the outside of the apop-
totic cells was determined by anannexin V-fluorescein
isothiocyanate (FITC) Apoptosis kit (KeyGene). In brief,
to detect early apoptosis, late apoptosis, and necrosis
induced by compound 1a, we plated the 3T3-L1 adipo-
cytes at a density of 1 × 106 cells/dish in a 60-mm dish and
exposed them for 24 h at 37°C. Cells were harvested by
centrifugation and washed with ice-cold PBS twice; the
cells were then stained with 20 μL of annexin V-FITC and
20 μL of PI at room temperature for 15 min in the dark.
Annexin V-FITC and PI emissions were detected in the
FL1 and FL2 channels of a FACScan flow cytometer (BD
FACSC anto™), using emission filters of 525 nm and 575
nm. The percentages of distribution of normal cells and
cells in early apoptosis, late apoptosis and necrosis were
calculated by CellQuest software (BD Biosciences).
Statistical Analysis
Data are presented as the mean ± SD. Data were analyzed
by one-way ANOVA using Statistical Package for Social
Science (SPSS, Chicago, IL). Differences were considered
to be significant at p < 0.05.
Results
Body mass (BM) and fat mass
After 4 weeks' induction, mice fed with HFD had 5.3%
higher body weights compared with normal group fed
with LFD (p < 0.05). The obese model was made success-
fully. Four-week treatment later, low dosage group and
high dosage group had 6.86% and 12.33% lower body
weights (p < 0.05) than model group respectively
(Fig.2A). No obvious difference was found between nor-
mal group and high dosage group. As compound 1a dos-
age doubled, the weight loss compared with model group
increased. The weight loss displayed dosage dependence.
White adipose tissue mass was also significantly
increased by 148% in model group compared with normal
group (p < 0.05) (Fig.2B). In response to compound 1a at
high dosage, the adipose tissue weights in high dosage
group were significantly decreased by 35.29% compared
with the model group (p < 0.05). The result inferred that
compound 1a inhibited HFD-induced body weight gain
and adipose tissue mass in mice effectively.
Inhibition ratio OD OD experimental group blank group =− × (/ ) 1 100 0%Yao et al. Lipids in Health and Disease 2010, 9:49
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Changes in lipid profiles
To determine whether compound 1a  has beneficial
effects on the circulating lipid profiles, we tested its
effects on serum triglyceride and cholesterol levels. Com-
pared with normal group, serum levels of triglycerides
and total cholesterol in model group were increased by
21.32% (p < 0.05) and 164% (p < 0.05) respectively
(Fig.3A). This result suggested that the high lipid model
was made successfully. After treatment, compound 1a
(high dosage) caused significant reductions in serum trig-
lyceride and total cholesterol levels by 28% (p < 0.05) and
46% (p < 0.05) respectively, compared with model group.
It was worthy noted that serum HDL-C in high dosage
group was much higher than that in other groups (p <
Figure 2 Effects of compound 1a on C57BL/6J mice. A: Effects of compound 1a on the weight of the mice after treatment. B: Effects of compound 
1a on the weight of the adipose tissue after treatment. Normal group: low fat diet; Model group: high fat diet; Low dosage group: high fat diet+50 
mg·kg-1 compound 1a; High dosage group: high fat diet+100 mg·kg-1 compound 1a; Control group: high fat diet+200 mg·kg-1 Inositol Hexanicotinate. 
All values are mean ± SD (n = 10), * presents P < 0.05 compared with model group. ** presents P < 0.05 compared with normal groupYao et al. Lipids in Health and Disease 2010, 9:49
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0.05). Consequently, we believed that compound 1a sup-
pressed lipid disorders through increasing HDL-C and
depressing TG, thereby preventing hypertriglyceridemia
and hypercholesterolemia.
Changes in serum leptin
The serum leptin level in model group was much higher
than that in normal group (p < 0.05). The result implied
that obesity mice accompanied with leptin resistance.
Figure 3 Effects of compound 1a on serum lipids and leptin. A: Changes in TG, TC, LDL-C and HDL-C by compound 1a in high-fat diet fed obese 
mice. Compound 1a-treated mice had significantly lower serum concentration of triglycerides and higher HDL-C compared with high-fat diet alone. 
B: Effects of compound 1a on serum leptin. Serum leptin concentration was reduced by compound 1a in a concentration dependent manner. Normal 
group: low fat diet; Model group: high fat diet; Low dosage group: high fat diet+50 mg·kg-1 compound 1a; High dosage group: high fat diet+100 
mg·kg-1 compound 1a; Control group: high fat diet+200 mg·kg-1 Inositol Hexanicotinate. All values are mean ± SD (n = 10), * presents P < 0.05 com-
pared with model group. ** presents P < 0.05 compared with normal group.Yao et al. Lipids in Health and Disease 2010, 9:49
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Compound 1a (high dosage) caused significant reduction
in serum leptin by 52.21% (p < 0.05) compared with
model group and reduced serum leptin in a dose- depen-
dent manner (Fig. 3B).
The results suggested that compound 1a could improve
leptin resistance induced by obesity.
Hepatic lipid accumulation
The hepatic accumulation of lipid was observed in mice
hepatic tissue slice by light microscopy. Mice in model
group showed considerable hepatic lipid accumulation
compared with that in normal group.
The mice hepar in high dosage group showed consider-
ably lower hepatic lipid accumulation than in model
group. As shown in Fig.4, the triglyceride droplets
appeared in mice hepar were almost completely disap-
peared by compound 1a treatment. Thus, the result sug-
gested that compound 1a could increase fat catabolism in
the liver and inhibited hepatic lipid accumulation.
Proliferation and differentiation of 3T3-L1
To determine whether compound 1a inhibited the cell
viability of 3T3-L1 preadipocytes, cells were treated with
four various doses of compound 1a and Inositol Hexanic-
otinate. Cell viability was estimated by the MTT assay
and compound 1a treatment inhibited cell growth in a
dose-dependent manner (Fig.5). When it reached 0.1
mmol·L-1, the viability was suppressed by 28.31%. To
examine the effect of compound 1a  on adipogenesis,
3T3-L1 preadipocytes were treated with adipogenic hor-
mone mixture in the absence or presence of compound
1a. During 3T3-L1 cell differentiation, the number of
larger lipid droplets in cells decreased. After 10 days, trig-
lyceride content of 3T3-L1 cells treated with compound
1a was measured. It exhibited a significant dose-depen-
dent decrease in the intracellular accumulation of triacyl-
glycerol under Oil-Red-O staining (Fig.6). However, there
was no significant difference between Inositol Hexanico-
tinate group and the control group.
Apoptosis assays
An increase in apoptotic nuclei in both preadipocytes
and mature adipocytes treated with 0.1 mmol·L-1 com-
pound 1a were evident from photos of Hoechst-33342
staining (data not show). We suggested that apoptosis
was induced by the compound 1a both in preadipocytes
and in mature adipocytes.
To quantify the modes of cell death induced by com-
pound  1a, 3T3-L1 preadipocytes and adipocytes were
treated with series concentration of compound 1a(1 × 10-
4, 1 × 10-5, 1 × 10-6, 1 × 10-7mol·L-1) for 24 h, were sub-
jected to simultaneous staining with annexin V-FITC and
PI, and were analyzed by FACScan flow cytometry.
Annexin V-FITC/PI double-staining analysis demon-
strated that the number of normal cells decreased in a
dose-dependent manner exposed to compound 1a. The
apoptotic cells, including early apoptosis and late apopto-
sis, were increased in a dose-dependent manner. When
the compound 1a concentration elevated to 0.1 mmol·L-1,
the percentage of cells in G3 decreased from 52.2% to
35.9% (preadipocytes) and from 86.1% to 72% (adipo-
cytes), respectively; cells in G2 and G4, including early
and late apoptosis, increased from 47.8% to 64.1% (pread-
ipocytes) and from 13.3% to 27.4%(adipocytes), respec-
tively (Table.1, Fig.7).
The result demonstrated that compound 1a could
induce apoptosis of both preadipocytes and mature adi-
pocytes.
Discussion
Obesity is the result of an energy imbalance caused by an
increased ratio of caloric intake to energy expenditure. In
conjunction with obesity, related metabolic disorders
such as dyslipidemia, atherosclerosis, and type 2 diabetes
have become global health problems. As well as diet and
exercise, some drugs are useful for weight reduction. To
date, only sibutramine and orlistat have been approved
for use, though both have poor outcomes and are not so
well tolerated [22]. Rimonabant is a selective CB1 recep-
tor blocker which has been proven effective in achieving
substantial weight loss and in reducing triglyceride levels
and glycohemoglobin. It has also been shown to increase
HDL cholesterol levels in obese patients and specifically
in patients with diabetes [23-25]. However, it was
reported that sibutramine, orlistat and Rimonabant had
several serious adverse effects in clinic, including gastro-
intestinal adverse effect and significant unfavorable
effects on cardiovascular system. As a result, much safer
therapeutic is necessary. In addition, there has been a
large increase in the use of complementary treatments
such as herbal remedies in the treatment of these diseases
over the past decade [26].
W e  o bs e rv ed  t h a t  m i c e  f ed  wi t h  HF D  s u p p l e m e n t ed
with compound 1a for 4 weeks had lower levels of serum
triglycerides, LDL-C and higher levels of HDL-C com-
pared with mice fed with HFD alone, which indicated
that compound 1a efficiently regulated triglyceride and
cholesterol metabolism in obese mice. Thus, compound
1a may be beneficial for treating patients with hypercho-
lesterolemia and hypertriglyceridemia.
Lipids are transported in the body by a sophisticated
lipoprotein transport system. Lipoproteins are divided
into 5 main classes according to their density: chylomi-
crons, VLDL-C, IDL-C, LDL-C and HDL-C [27]. LDL-C
is a risk factor for CAD. The antagonist of LDL-C is HDL-
C. It collects cholesterol from body tissues and returns it
to the liver. As a result, HDL-C cholesterol levels are
inversely related to this risk [28]. Compound 1a  wasYao et al. Lipids in Health and Disease 2010, 9:49
http://www.lipidworld.com/content/9/1/49
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Figure 4 Inhibition of hepatic lipid accumulation by compound 1a in high-fat diet-fed obese mice. Histological analyses of hepatic lipid accu-
mulation. Representative HE-stained liver sections are shown (original magnification 200×). A presents the normal hepatocyte appearance. High fat 
diet induced hepatocytes necrosis was shown in B. After the treatment of compound 1a, necrosis hepatocytes are reduced, especially in D. Small lipid 
drops were seen C. There were obvious lipid drops in E. A: low fat diet (normal group); B: high fat diet (model group); C: high fat diet+50 mg·kg-1 com-
pound 1a (low dosage group); D: high fat diet+100 mg·kg-1 compound 1a (high dosage group); E: high fat diet+200 mg·kg-1 Inositol Hexanicotinate 
(control group).Yao et al. Lipids in Health and Disease 2010, 9:49
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determined to effectively in elevating HDL-C. Thus, we
tentatively put forward that compound 1a was effective in
reversing coronary artery disease.
In parallel with its effect on serum TG, mice fed with
HFD supplemented with compound 1a had significantly
lower adipose tissue mass and body weight gain than that
fed with HFD alone. This correlated with reports showed
that the lipids in adipose tissue were largely derived from
circulating triglycerides, especially during HFD feeding
[29,30] and that the reductions in serum TG also led to
decreased adipose tissue mass [31-33].
Increased lipid accumulation in hyperlipidemic rats
and mice may be due to increased levels of triglyceride
depots in the liver [33]. Histological analysis in our
research showed that HFD-fed mice had considerable
hepatic lipid accumulation. After 4-week treatment with
compound  1a, hepatic lipid accumulation disappeared
(high dosage group). Long term hepatic lipid accumula-
tion would cause fatty liver. Thus the result suggested
that compound 1a could recover fatty liver induced by
lipid accumulation.
Leptin, a 167-amino acid protein, is synthesized and
secreted mainly by adipose tissue [34,35]. Adipose tissue
produces the hormone leptin in approximate proportion
to fat stores. Circulating leptin communicates the level of
energy reserves in the periphery to the central nervous
system (CNS) in order to suppress food intake and permit
energy expenditure [34,36-38]. Peripheral administration
of exogenous leptin results in a specific reduction in body
fat mass with no change in lean mass in experimental ani-
mals [39] or in obese humans on a weight-reducing diet
[40], but elevated concentrations of endogenous leptin do
not appear to be capable of preventing, or reversing, the
accumulation of adipose tissue during, or after, the devel-
opment of obesity [41]. Several authors have reported
that aging [42,43] or the consumption of a HFD [44-46]
results in the development of leptin resistance in rodents,
measured as a failure of leptin either to inhibit food
intake or to induce weight loss. Increased circulating lep-
tin, a marker of leptin resistance, is common in obesity
and independently associates with insulin resistance [47]
and CVD [48-51] in humans. In our study, Serum leptin
in model group was raised during the induction of HFD
to 694.76 pg·mL-1. After the treatment of 100 mg·kg-1
compound 1a, the serum leptin was reduced to 52.21%
compared with model group. It suggested that compound
1a was effective to leptin resistance induced by HFD in
mice.
The possible mechanisms for the treatment of obesity
are as follows: balance energy intake and expenditure,
reduce preadipocyte differentiation, decrease lipogenesis,
increase lipolysis and induce adipocyte apoptosis [52].
Adipocytes play an important role in lipid homeostasis
and energy balance by relating to triglyceride storage and
Figure 5 Effect of compound 1a on the inhibition of cell viability in 3T3-L1 preadipocytes. After the influence reached 80%, 3T3-L1 preadipo-
cytes were incubated with compound 1a, at the indicated concentration (1 × 10-7, 1 × 10-6, 1 × 10-5, 1 × 10-4mol L-1) for 48 h; growth rate was assessed 
by MTT assay. The inhibition ratio was calculated by formula 1. All values are mean ± SD (n = 3)Yao et al. Lipids in Health and Disease 2010, 9:49
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free fatty acids release. Adipocyte differentiation and the
amount of fat accumulation are associated with the
occurrence and development of obesity [53]. Moreover,
adipocyte produces and secretes dozens of factors such as
leptin, adiponectin, resistin, visfatin, TNF-α, and IL-6,
which participate in energy metabolism of adipose tissue
itself and the whole body either in an auto/paracrine or
an endocrine fashion [54]. For these reasons, anti-obesity
works have been conducted in 3T3-L1 adipocytes.
Anti-obesity effect of compound 1a in the 3T3-L1 cell
model was measured in our study. Any reduction in adi-
pocyte number can result from preadipocyte or adipo-
cyte apoptosis, as well as adipocyte dedifferentiation [55].
In this study we investigated the effects of compound 1a
on adipocyte viability, apoptosis and lipid accumulation
during adipogenesis in 3T3-L1 cells. We found that com-
pound 1a inhibited cell viability and enhanced apoptosis
in both pre- and mature adipocytes. Correspondingly, the
Figure 6 Effect of compound 1a on lipid adipogenesis. A: Effect of compound 1a on lipid accumulation in 3T3-L1 adipocytes. At two days after 
confluence, 3T3-L1 cells were differentiated by MDI. At day 8 compound 1a was given to the cells at series of concentrations. Ten days after differen-
tiation, we measured triglyceride content of 3T3-L1 cells treated with compound 1a by Oil-Red-O staining. The inhibition ratio was calculated by for-
mula 1. B: Effect of vehicle, compound 1a, Inositol Nicotinate on the lipid accumulation by Oil-Red-O staining. Images of the stained lipid droplets 
were collected on a fluorescence microscope. Lipid accumulation was significantly decreased treated by compound 1a. All values are mean ± SD (n 
= 3).Yao et al. Lipids in Health and Disease 2010, 9:49
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lipid accumulation was suppressed during the differentia-
tion process. As to in vivo experiment, the adipose was
depauperated, which was coincident with the weight and
adipose tissue loss.
Lipolysis is a property of mature, differentiated adipo-
cytes. Adipocyte maturation requires an elaborate
sequence of events associated with specific patterns of
transcription factors at different phases of differentiation
[56]. Mature adipocytes have massive TG storage com-
pared with any other tissue, despite having a well-devel-
oped lipolytic capacity. Conversely, a decrease of
adipocyte differentiation, which by definition is associ-
ated with reduction of the lipid droplet volume, will tran-
siently be accompanied by a net increase in lipolysis, and
this is one potential mechanism for increasing lipolysis.
As an important component in the network of lipid
energy metabolism, adipocyte lipolysis is positioned to
affect the fat content of liver, muscle, heart and kidney in
obesity.
In conclusion, the results of the in vivo and in vitro
study show that compound 1a regulates serum lipid pro-
files, decreases adipose tissue mass and body weight gain
by inducing adipocyte apoptosis. The compound 1a may
be used to treat obese patients with hypercholesterolemia
and hypertriglyceridemia. The adipocyte apoptosis
mechanism induced by compound 1a  will be further
researched.
Abbreviations
CAD: Coronary Artery Disease; CNS: Central nervous system; CVD: Cardiovascu-
lar disease; DEX: Dexamethasone; DMEM: Dulbecco's modified Eagle's
medium; FBS: Fetal bovine serum; HFD: High fat diet; HDL-C: High density lipo-
protein cholesterol; HE: Hematoxylin and eosin; IBMX: 3-Isobutyl-1-methylxan-
thine; IL-6: Interleukin-6; LDL-C: Low density lipoprotein cholesterol; LFD: Low
fat diet; MTT: 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide;
Table 1: Preadipocytes(table.1-1) and mature adipocytes(table.1-2) were incubated in vitro without or with 1 × 10-7, 1 × 
10-6, 1 × 10-5, 1 × 10-4 mol·L-1 of compound 1a for 24 h and analyzed by Annexin V/PI cell viability assay. 
1-1
%Parent blank 1*10-7 1*10-6 1*10-5 1*10-4
Q1 1.7 2.5 1.8 2.8 1.5
Q2 39.0 38.5 39.2 41.6 43.2
Q3 50.5 47.6 46.7 39.5 34.4
Q4 8.8 11.2 12.4 16.0 20.9
1-2
Q1 0.5 0.2 0.5 0.1 0.5
Q2 1.8 1.3 1.5 1.4 2.7
Q3 86.1 85.8 85.4 81.2 72
Q4 11.5 12.8 12.6 17.3 24.7
Apoptotic (Q4+Q2) cells were identified and expressed as a percentage of total dead cells.
Figure 7 Apoptosis ratios (apoptosis cell number in treatment 
group/apoptosis cell number in blank group) after 24 h were 
shown in this picture. With the concentration increase, the apoptosis 
ratio was raised both in preadipocytes and mature adipocytes. The 
phenomenon was more notable in mature adipocytes induced by 1 × 
10-4 mol·L-1 compound 1a, whose apoptosis ratio reached almost 
206% compared with DMSO group.Yao et al. Lipids in Health and Disease 2010, 9:49
http://www.lipidworld.com/content/9/1/49
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PBS: Phosphate buffered saline; TC: Total cholesterol; TG: Triglyceride; TNF-α:
Tumor necrosis factor-α.
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